Culprit and victim - DNA topoisomerase II

Lancet Oncology

Volumn 3, Issue 4, 2002, Pages 235-243

  Kellner, Udo ^a   Sehested, Maxwell ^b   Jensen, Peter B ^b   Gieseler, Frank ^c   Rudolph, Pierre ^d  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

^b Rigshospitalet   (Denmark)

^c UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^d UNIVERSITY OF KIEL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

5 CHLOROSULFAQUINOXALINE; ACLARUBICIN; AMSACRINE; ANTHRACYCLINE; ANTHRAQUINONE; ANTINEOPLASTIC AGENT; BLEOMYCIN; CARBAMIC ACID DERIVATIVE; CHLOROQUINE; CISPLATIN; CYCLOPHOSPHAMIDE; DAUNORUBICIN; DNA TOPOISOMERASE (ATP HYDROLYSING); DOXORUBICIN; EPIPODOPHYLLOTOXIN; EPIPODOPHYLLOTOXIN DERIVATIVE; EPIRUBICIN; ETOPOSIDE; GENOMIC DNA; GYRASE INHIBITOR; IDARUBICIN; MITOXANTRONE; PIPERAZINE DERIVATIVE; PREDNISONE; RAZOXANE; SOBUZOXANE; TENIPOSIDE; TRASTUZUMAB; UNCLASSIFIED DRUG; VINBLASTINE; XK 469;

CANCER CHEMOTHERAPY; CANCER RESISTANCE; CARDIOTOXICITY; CELL DIVISION; CELL KILLING; DISEASE COURSE; DNA DAMAGE; DNA REPLICATION; DNA STRUCTURE; DRUG DESIGN; DRUG MECHANISM; DRUG TARGETING; ENZYME ACTIVITY; HUMAN; PHYLOGENY; PREDICTION; PRIORITY JOURNAL; REVIEW;

EID: 0036227720     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(02)00715-5     Document Type: Review

References (86)

1. Structure and mechanism of DNA topoisomerase II
2. DNA topoisomerases: New break for archael enzyme
3. The clinical pharmacology of etoposide
4. Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II
5. Investigating the biological functions of DNA topoisomerases in eukaryotic cells
6. Cloning and sequencing of cDNA encoding human DNA topoisomerase II and localization of the gene to chromosome region 17q21-22
7. Isolation of cDNA clones encoding the beta isozyme of human DNA topoisomerase II and localisation of the gene to chromosome 3p24
8. Active heterodimers are formed from human DNA topoisomerase II α and II β isoforms
9. DNA topoisomerases
10. Studies on the role of topoisomerases in general, gene- and strand- specific DNA repair
11. Enhanced expression of Ki-67, topoisomerase IIα, PCNA, p53 and p21WAF1/Cip1 reflecting proliferation and repair activity in UV-irradiated melanocytic nevi
12. Physiological regulation of eukaryotic topoisomerase II
13. Proliferation- and cell cycle-dependent differences in expression of the 170 kilodalton and 180 kilodalton forms of topoisomerase II in NIH-3T3 cells
14. Cell-cycle regulation of the DNA topoisomerase IIα promoter is mediated by proximal CCAAT boxes: Possible involvement of acetylation
15. Amsacrine-promoted DNA cleavage site determinants for the two human DNA topoisomerase II isoforms alpha and beta
16. Murine transgenic cells lacking DNA topoisomerase IIβ are resistant to acridines and mitoxantrone: Analysis of cytotoxicity and cleavable complex formation
17. DNA topoisomerase IIβ and neural development
18. Molecular cloning and characterization of the human topoisomerase IIα and IIβ genes: Evidence for isoform evolution through gene duplication
19. Extracellular signal-regulated kinase activates topoisomerase IIα through a mechanism independent of phosphorylation
20. Detection of human topoisomerase II alpha in cell lines and tissues: Characterization of five novel monoclonal antibodies
21. Recuitment of cdc2 kinase by DNA topoisomerase II is coupled to chromatin remodeling
22. Inhibition of DNA topoisomerase IIα gene expression by the p53 tumor suppressor
23. Human topoisomerase IIα and IIβ interact with the C-terminal region of p53
24. The response of eukaryotic topoisomerases to DNA damage
25. Gadd45, a p53-responsive stress protein, modifies DNA accessibility on damaged chromatin
26. Effects of wild-type p53 expression on the quantity and activity of topoisomerase IIα and β in various human cancer cell lines
27. Functional interaction between human topoisomerase IIα and retinoblastoma protein
28. The cell cycle: Theory and applications to cancer
29. 14-3-3 proteins: Key regulators of cell division, signalling and apoptosis
30. Modulation of human DNA topoisomerase IIα function by interaction with 14-3-3ε
31. Chromosomal DNA loops may constitute basic units of the eukaryotic genome organization and evolution
32. Chromosome recombination and defective genome segregation induced in Chinese hamster cells by the topoisomerase II inhibitor VM-26
33. Chemotherapy-related, late-occuring, Philadelphia chromosome in AML, ALL and CML: Similar events related to treatment with DNA topoisomerase II inhibitors?
34. Crystal structure of NaeI: An evolutionary bridge between DNA endonuclease and topoisomerase
35. Chromosome organization and gene expression
36. Mutagenic properties of topoisomerase-targeted drugs
37. Expression of topoisomerase IIα is associated with rapid cell proliferation, aneuploidy, and c-erbB2 overexpression in breast cancer
38. Amplification of the topoisomerase II α gene in a non-small cell lung cancer cell line and charaterisation of polymorphisms at the human topoisomerase IIα and β loci in normal tissue
39. Topoisomerase II α co-amplification with erbB2 in human primary breast cancer and breast cancer cell lines: Relationship to m-AMSA and mitoxantrone sensitivity
40. KiS1-a novel monoclonal antibody which recognizes proliferating cells: Evaluation of its relationship to prognosis in mammary carcinoma
41. Diagnostic assessment of two novel proliferation-specific antigens in benign and malignant melanocytic lesions
42. Prognostic relevance of a novel proliferation marker, Ki-S11, for soft-tissue sarcoma: A multivariate study
43. Prognostic significance of ki-67 and topoisomerase IIα expression in infiltrating ductal carcinoma of the breast
44. Correlation between p53, c-erbB-2, and topoisomerase IIα expression, DNA ploidy, hormonal receptor status and proliferation in 356 node-negative breast carcinomas: Prognostic implications
45. Clinical applications of anticancer drugs targeted to topoisomerase II
46. Cell death induced by topoisomerase-targeted drugs: More questions than answers
47. Caspase activation in MCF7 cells responding to etoposide treatment
48. DNA topoisomerase I and II as targets for rational design of new anticancer drugs
49. A redox pathway leading to the alkylation of nucleic acids by doxorubicin and related anthracylines: Application to the design of antitumor drugs for resistant cancer
50. Changes in nuclear protein kinase C-delta holoenzyme, its catalytic fragments, and its activity in polyomavirus-transformed pyF111 rat fibroblasts while proliferating and following exposure to apoptogenic topoisomerase II inibitors
51. Anthracycline drug targeting: Cytoplasmic versus nuclear-a fork in the road
52. Human topoisomerase II function, tyrosine phosphorylation and cell cycle checkpoints
53. Therapy-related acute lymphoblastic leukaemia with MLL rearrangement following DNA topoisomerase II inhibitors, an increasing problem: Report on two new cases and review of the literature since 1992
54. Secondary acute myelogenous leukemia and myelodysplasia without abnormalities of chromosome 11q23 following treatment of acute leukemia with topoisomerase II-based chemotherapy
55. Relationship between topoisomerase II levels and resistance to topoisomerase II inhibitors in lung cancer all lines
56. Immunoexpression of DNA topoisomerase IIα predicts reponse to primary chemotherapy in breast cancer patients
57. Immunohistochemical expression of topoisomerase IIalpha (Topo IIα) and multidrug resistance-associated protein (MRP), plus chemosensitivity testing, as chemotherapeutic indices of ovarian and endometrial carcinomas
58. Amplification and deletion of topoisomerase IIα associate with ErbB-2 amplification and effect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer
59. Induction of sensitivity to doxorubicin and etoposide by transfection of MCF-7 breast cancer cells with heregulin beta-2
60. Enhanced etoposide sensitivity following adenovirus-mediated human topoisomerase IIalpha gene transfer is independent of topoisomerase IIbeta
61. Topoisomerase II activities in AML and their correlation with cellular sensitivity to anthracyclines and epipodophyllotoxines
62. Etoposide targets topoisomerase IIα and IIβ in leukemic cells: Isoform-specific cleavable complexes visualized and quantified in situ by a novel immunofluorescence technique
63. Absence of topoisomerase IIβ in an amsacrine-resistant human leukemia cell line with mutant topoisomerase IIα
64. Chloroquinoxaline sulfonamide (NSC 339004) is a topoisomerase IIα/β poison
65. XK469, a selective topoisomerase IIβ poison
66. The immunohistochemical marker Ki-S2: Cell cycle kinetics and tissue distribution of a novel proliferation-specifc antigen
67. Concurrent overexpression of p53 and c-erB-2 correlates with accelerated cycling and concomitant poor prognosis in node-negative breast cancer
68. Preclinical antitumor efficacy of analogs of XK469: Sodium-(2-[4-(7-chloro-2- quinoxalinyloxy)phenoxy]propionate
69. ICRF-187 rescue in etoposide treatment in vivo: A model targeting high-dose topoisomerase II poisons to CNS tumors
70. Treatment of anthracycline extravasation with dexrazoxane
71. Targeting the cytotoxicity of topoisomerase II-directed epipodophyllotoxins to tumor cells in acidic environments
72. Merbarone, a catalytic inhibitor of DNA topoisomerase II, induces apoptosis in CEM cells through activation of ICE/CED-3-like protease
73. Multidrug resistance and its reversal
74. P-glycoprotein as a drug target in the treatment of multidrug resistant cancer
75. Altered DNA topoisomerase II activity in Chinese hamster cells resistant to topoisomerase II inhibitors
76. Altered catalytic activity of and DNA cleavage by DNA topoisomerase II from human leukemic cells selected for resistance to VM-26
77. Identification of a point mutation in the topoisomerase II gene from a human leukemia cell line containing an amsacrine-resistant form of topoisomerase II
78. Functional expression of human topoisomerase IIα in yeast: Mutations at amino acids 450 or 803 of topoisomerase IIα result in enzymes that can confer resistance to anti-topoisomerase II agents
79. DNA topoisomerase II mutations and resistance to anti-tumor drugs
80. Cleavage of the Bloom's syndrome gene product during apoptosis by caspase-3 results in an impaired interaction with topoisomerase IIIα
81. Differential effects of the poly (ADP-ribose) polymerase (PARP) inhibitor NU1025 on topoisomerase I and II inhibitor cytotoxicity in L1210 cells in vitro
82. DNA intercalation, topoisomerase II inhibition and cytotoxic activity of the plant alkaloid neocryptolepine
83. Single-strand conformational polymorphism analysis of the M(r) 170,000 isozyme of DNA topoisomerase II in human tumor cells
84. Topoisomerase II levels and drug sensitivity in adult acute myelogenous leukemia
85. Point mutations of the topoisomerase IIα gene in patients with small cell lung cancer treated with etoposide
86. Loss of amino acids 1490Lys-Ser-Lys1492 in the COOH-terminal region of topoisomerase IIα in human small cell lung cancer selected for resistance to etoposide results in an extranuclear enzyme localization